S&P 500
7,556.20
-0.01%
Dow Jones
52,607.50
0.00%
Nasdaq 100
29,623.90
-0.03%
Russell 2000
2,965.77
-0.08%
FTSE 100
10,497.60
-0.13%
Nikkei 225
68,340.10
+0.20%

Investing

Pfizer Loses Court Case on Menopause Drug (PFE)

Photo of Paul Ausick
By Paul Ausick Published

A state appeals court in Pennsylvania has sided with two women who filed suit against drugmaker Pfizer Inc. (NYSE: PFE) claiming that the company’s Prempro menopause drug caused their breast cancers. The award of $45 million will be split between the two complainants.

Pfizer has set aside $840 million to pay claims against Prempro, which was linked to breast cancer in a 2002 study sponsored by the National Institutes of Health. So far the company has resolved about 46% of the litigation resulting from claims against the drug, which is still available. Prempro was developed and sold by Wyeth prior to the 2009 merger takeover by Pfizer.

Pfizer has said that it will appeal the ruling to the Pennsylvania Supreme Court.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

3 Big Pharma Stocks With Credible Threats to Their Blockbusters
Trey Thoelcke |

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an…

Lee Jackson |

4 Pharmaceutical Companies Leading the Breast Cancer Fight

In a new report, the RBC team focused on the companies that are making the most progress with treatments for…

Jon C. Ogg |

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Douglas A. McIntyre |

Generic Companies Hoping MedImmune Solves Bottleneck Problem

by Aaron F. Barkoff We reported last month on a new declaratory judgment action that Apotex filed against GlaxoSmithKline (GSK)…

Douglas A. McIntyre |

Pfizer: More Big Pharma R&D Work Fails

Pfizer (PFE) and other big pharma companies have been under assault for several years as some of their most profitable drugs…

What to Expect From Pfizer Earnings
Chris Lange |

What to Expect From Pfizer Earnings

Pfizer is scheduled to report its fourth-quarter financial results before the markets open on Tuesday.

Trey Thoelcke |

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the…

Paul Ausick |

Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent

Wikimedia CommonsShares of drug maker Pfizer Inc. (NYSE: PFE) were halted Wednesday afternoon at $32.29, down about 0.4% from the…

Jon C. Ogg |

Pfizer Dodges a Bullet on Earnings

Pfizer has reported better-than-expected first-quarter earnings and revenue and offered guidance.

Top Gaining Stocks

CrowdStrike
CRWD • Vol: 11,983,479
Goldman Sachs
GS • Vol: 3,787,930
Dell Technologies
DELL • Vol: 7,221,916
Palo Alto Networks
PANW • Vol: 5,890,623
Monolithic Power Systems
MPWR • Vol: 777,496

Top Losing Stocks

IBM
IBM • Vol: 67,221,239
Coterra Energy
CTRA • Vol: 73,319,495
Biogen
BIIB • Vol: 3,821,790
HCA Healthcare
HCA • Vol: 4,227,565
Intuitive Surgical
ISRG • Vol: 5,651,099